Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniela Toneatto

Showing results (21-30 of 50) with videos related to

Pageof 5
Sort By:
Msphere|April 8, 2025
Methods to evaluate the performance of a multicomponent meningococcal serogroup B vaccineRay Borrow, Laura Tomasi Cont, Daniela Toneatto, et al.
Vaccine|February 9, 2006
An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccineGiuseppe Del Giudice, Anne Katrin Hilbert, Roberto Bugarini, et al.
Human Vaccines|July 8, 2011
Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adultsDaniela Toneatto, Philipp Oster, A Corine W deBoer, et al.
Vaccine|December 4, 2016
A phase III observer-blind randomized, controlled study to evaluate the immune response and the correlation with nasopharyngeal carriage after immunization of university students with a quadrivalent meningococcal ACWY glycoconjugate or serogroup B meningococcal vaccineRobert C Read, Peter Dull, Xilian Bai, et al.
Human Vaccines & Immunotherapeutics|July 8, 2024
4CMenB journey to the 10-year anniversary and beyondVéronique Abitbol, Federico Martinón-Torres, Muhamed-Kheir Taha, et al.
Human Vaccines & Immunotherapeutics|July 2, 2013
Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccineMaria Elena Santolaya, Miguel O'Ryan, María Teresa Valenzuela, et al.
Vaccine|March 21, 2017
Immunogenicity and safety of concomitant administration of meningococcal serogroup B (4CMenB) and serogroup C (MenC-CRM) vaccines in infants: A phase 3b, randomized controlled trialMarco Aurelio P Safadi, Federico Martinon-Torres, Lily Yin Weckx, et al.
Human Vaccines & Immunotherapeutics|October 24, 2018
Evaluation of strain coverage of the multicomponent meningococcal serogroup B vaccine (4CMenB) administered in infants according to different immunisation schedulesAlessia Biolchi, Sara Tomei, Laura Santini, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|March 25, 2015
Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 monthsFiona McQuaid, Matthew D Snape, Tessa M John, et al.
The Pediatric Infectious Disease Journal|April 12, 2014
Persistence of bactericidal antibodies to 5 years of age after immunization with serogroup B meningococcal vaccines at 6, 8, 12 and 40 months of ageFiona McQuaid, Matthew D Snape, Tessa M John, et al.
Pageof 5

Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
Msphere|April 8, 2025
Methods to evaluate the performance of a multicomponent meningococcal serogroup B vaccineRay Borrow, Laura Tomasi Cont, Daniela Toneatto, et al.
Vaccine|February 9, 2006
An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccineGiuseppe Del Giudice, Anne Katrin Hilbert, Roberto Bugarini, et al.
Human Vaccines|July 8, 2011
Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adultsDaniela Toneatto, Philipp Oster, A Corine W deBoer, et al.
Vaccine|December 4, 2016
A phase III observer-blind randomized, controlled study to evaluate the immune response and the correlation with nasopharyngeal carriage after immunization of university students with a quadrivalent meningococcal ACWY glycoconjugate or serogroup B meningococcal vaccineRobert C Read, Peter Dull, Xilian Bai, et al.
Human Vaccines & Immunotherapeutics|July 8, 2024
4CMenB journey to the 10-year anniversary and beyondVéronique Abitbol, Federico Martinón-Torres, Muhamed-Kheir Taha, et al.
Human Vaccines & Immunotherapeutics|July 2, 2013
Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccineMaria Elena Santolaya, Miguel O'Ryan, María Teresa Valenzuela, et al.
Vaccine|March 21, 2017
Immunogenicity and safety of concomitant administration of meningococcal serogroup B (4CMenB) and serogroup C (MenC-CRM) vaccines in infants: A phase 3b, randomized controlled trialMarco Aurelio P Safadi, Federico Martinon-Torres, Lily Yin Weckx, et al.
Human Vaccines & Immunotherapeutics|October 24, 2018
Evaluation of strain coverage of the multicomponent meningococcal serogroup B vaccine (4CMenB) administered in infants according to different immunisation schedulesAlessia Biolchi, Sara Tomei, Laura Santini, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|March 25, 2015
Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 monthsFiona McQuaid, Matthew D Snape, Tessa M John, et al.
The Pediatric Infectious Disease Journal|April 12, 2014
Persistence of bactericidal antibodies to 5 years of age after immunization with serogroup B meningococcal vaccines at 6, 8, 12 and 40 months of ageFiona McQuaid, Matthew D Snape, Tessa M John, et al.
Pageof 5